Difei Yang
Stock Analyst at Mizuho
(1.97)
# 2,941
Out of 4,732 analysts
41
Total ratings
30.56%
Success rate
7.25%
Average return
Main Sectors:
Stocks Rated by Difei Yang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKBA Akebia Therapeutics | Downgrades: Neutral | $6 → $2 | $2.07 | -3.38% | 4 | Mar 31, 2022 | |
| BLUE bluebird bio | Maintains: Buy | $580 → $460 | $8.35 | +5,408.98% | 3 | Sep 22, 2021 | |
| NVCR NovoCure | Maintains: Neutral | $229 → $200 | $26.17 | +664.23% | 6 | Jul 30, 2021 | |
| CASI CASI Pharmaceuticals | Initiates: Buy | $38 | $2.62 | +1,350.38% | 1 | Apr 26, 2021 | |
| FGEN FibroGen | Downgrades: Neutral | $29 | $0.57 | +4,962.85% | 4 | Apr 7, 2021 | |
| QURE uniQure | Upgrades: Buy | $52 | $14.05 | +270.11% | 4 | Apr 1, 2021 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $158 → $160 | $118.00 | +35.59% | 2 | Feb 26, 2021 | |
| XERS Xeris Biopharma Holdings | Maintains: Buy | $18 → $14 | $3.20 | +337.50% | 4 | Apr 23, 2020 | |
| RVNC Revance Therapeutics | Maintains: Buy | $39 → $35 | $3.68 | +851.09% | 3 | Apr 1, 2020 | |
| NKTR Nektar Therapeutics | Upgrades: Buy | $21 → $35 | $0.89 | +3,823.77% | 4 | Feb 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $52 → $20 | $0.54 | +3,604.39% | 2 | Feb 27, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $2.53 | - | 2 | Aug 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $7.37 | +279.92% | 1 | Feb 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $1.63 | +1,617.79% | 1 | Sep 27, 2017 |
Akebia Therapeutics
Mar 31, 2022
Downgrades: Neutral
Price Target: $6 → $2
Current: $2.07
Upside: -3.38%
bluebird bio
Sep 22, 2021
Maintains: Buy
Price Target: $580 → $460
Current: $8.35
Upside: +5,408.98%
NovoCure
Jul 30, 2021
Maintains: Neutral
Price Target: $229 → $200
Current: $26.17
Upside: +664.23%
CASI Pharmaceuticals
Apr 26, 2021
Initiates: Buy
Price Target: $38
Current: $2.62
Upside: +1,350.38%
FibroGen
Apr 7, 2021
Downgrades: Neutral
Price Target: $29
Current: $0.57
Upside: +4,962.85%
uniQure
Apr 1, 2021
Upgrades: Buy
Price Target: $52
Current: $14.05
Upside: +270.11%
Sarepta Therapeutics
Feb 26, 2021
Maintains: Buy
Price Target: $158 → $160
Current: $118.00
Upside: +35.59%
Xeris Biopharma Holdings
Apr 23, 2020
Maintains: Buy
Price Target: $18 → $14
Current: $3.20
Upside: +337.50%
Revance Therapeutics
Apr 1, 2020
Maintains: Buy
Price Target: $39 → $35
Current: $3.68
Upside: +851.09%
Nektar Therapeutics
Feb 3, 2020
Upgrades: Buy
Price Target: $21 → $35
Current: $0.89
Upside: +3,823.77%
Feb 27, 2019
Downgrades: Neutral
Price Target: $52 → $20
Current: $0.54
Upside: +3,604.39%
Aug 8, 2018
Upgrades: Buy
Price Target: n/a
Current: $2.53
Upside: -
Feb 13, 2018
Initiates: Neutral
Price Target: $28
Current: $7.37
Upside: +279.92%
Sep 27, 2017
Initiates: Buy
Price Target: $28
Current: $1.63
Upside: +1,617.79%